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Seasonal changes in mammalian physiology, such as those affecting 
reproduction, hibernation and metabolism, are controlled by pituitary hormones 
released in response to annual environmental changes. In temperate zones, the 
primary environmental cue driving seasonal reproductive cycles is the change in 
daylength (photoperiod), encoded by the pattern of melatonin secretion from the 
pineal gland. However, although reproduction relies on hypothalamic 
gonadotrophin-releasing hormone (GnRH) output, and most cells producing 
reproductive hormones are in the pars distalis (PD) of the pituitary, melatonin 
receptors are localized in the pars tuberalis (PT), a physically and functionally 
separate part of the gland. How melatonin in the PT controls the PD is not 
understood. Here we show that melatonin time-dependently acts on its receptors 
in the PT to alter splicing of vascular endothelial growth factor (VEGF). Outside 
the breeding season, angiogenic VEGF-A stimulates vessel growth in the 
infundibulum, aiding vascular communication between the PT, PD and brain. This 
also acts on VEGFR2 expressed in PD prolactin-producing cells known to impair  
gonadotrophin secretion. In contrast, in the breeding season, melatonin releases 
anti-angiogenic VEGF-Axxxb from the PT, inhibiting infundibular angiogenesis and 
diminishing lactotroph VEGFR2 expression, lifting reproductive axis repression in 
response to shorter day lengths. The time-dependent, melatonin-induced 
differential expression of VEGF-A isoforms culminates in alterations in 
gonadotroph function opposite to those of lactotrophs, with up-regulation and 
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down-regulation of gonadotropin gene expression during the breeding and non-
breeding season, respectively. These results provide a novel mechanism by 
which melatonin can control pituitary function in a seasonal manner. 
  





Pituitary hormone secretion regulates multiple functions in the body, including 
fertility, growth, fluid balance and the response to stress. This regulation displays 
annual oscillations in most mammalian species, and is overtly seasonal in 
animals that have a tightly controlled reproductive window. It is thought that both 
endogenous (circadian and circannual rhythm generators) and exogenous 
(photoperiod) cues can contribute to drive seasonal physiology [1]. The duration 
of nocturnal release of the pineal hormone melatonin underlies the photoperiodic 
control of seasonality in sheep [2]. As the synthesis and release of melatonin is 
inhibited by light, the longer nights of winter are associated with longer duration 
of melatonin production, whereas the opposite is true in the summer. Even 
though the reproductive cycle relies primarily on the secretion of gonadotropin-
releasing hormone (GnRH) from the hypothalamus [3], one of the major sites of 
melatonin action is the pars tuberalis (PT) of the pituitary gland [4, 5]. Indeed, 
melatonin is a regulator of endocrine function in the pituitary, and specifically 
inhibits prolactin-producing lactotrophs, known to be associated with repression 
of the reproductive cycle, directly within this tissue [6]. However, the mechanism 
through which melatonin exerts this influence remains unclear.  
 
Three functionally distinct regions of the pituitary gland, the PT, pars distalis (PD) 
and infundibulum intercommunicate with one another via an elegant portal 
vascular arrangement. Although melatonin is known to act on its receptors in the 
PT, lactotrophs – the cells inhibited by melatonin, are exclusively found in the PD 
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[7, 8]. The mechanisms through which melatonin, acting in the PT, can control 
pituitary function in the PD are unresolved. Here we describe how the vascular 
arrangement in the infundibulum of the pituitary was drastically altered between 
the breeding and non-breeding seasons (BS and NBS, respectively) in sheep. 
We therefore tested the hypothesis that melatonin could act to regulate pituitary 
function through the control of blood vessel growth and communication between 
the PT and PD.  
Blood vessel growth (angiogenesis) is regulated by vascular endothelial growth 
factors (VEGF), a family of peptides of which the most potently angiogenic and 
widely expressed is VEGF-A. Multiple VEGF-A products can be generated by 
alternative splicing of a single gene [9, 10]. Alternative use of exons 6 and 7 will 
result in proteins of different length (e.g. 120, 164 or 188 amino acids in sheep, 
and 121, 165 or 189 in human). Use of the proximal splice site in exon 8 
generates the pro-angiogenic VEGF-Axxxa isoforms, and use of the distal splice 
site in exon 8 generates the VEGF-Axxxb isoforms, where xxx denotes the 
number of amino acids, and a or b denotes the carboxy-terminal amino acid 
sequence. The most extensively studied and highly expressed isoforms of each 
family (VEGF-A165b and VEGF-A165a, respectively) are able to counteract the 
effects of each other on blood vessel growth [11]. When VEGF-A165a binds 
VEGFR2 on endothelial cells it causes robust autophosphorylation and 
downstream signalling through phospholipase C, src, ras and other pathways to 
induce a raft of responses including angiogenesis, vasodilatation, increased 
vascular permeability and cytoprotection [12].  




Adaptation to seasonal changes in the environment is critical for survival in all 
species. In vertebrates, annual oscillations in pituitary hormones underlie the 
regulation of seasonal physiology. We found that, in sheep, the duration of pineal 
melatonin output at night controls the production of different forms of the protein, 
vascular endothelial growth factor (VEGF) within a specific pituitary region, the 
pars tuberalis. Forms that block blood-vessel growth are made in winter, but 
those that stimulate it are made in summer. Further to the resulting remodelling 
of the vascular connection between the brain and pituitary, the temporally 
divergent VEGF-A variants operate as messenger signals on endocrine cells of a 
different part of the gland, the pars distalis, to regulate seasonal fertility. 
 
In contrast, although the binding affinity for VEGFR2 is the same as that of 
VEGF-A165a, VEGF-A165b induces weak phosphorylation [13], does not bind the 
co-receptor Neuropilin-1 [14 ], which is responsible for intracellular trafficking and 
recycling to the membrane [15], and does not activate the full signalling pathway. 
This means it does not induce angiogenesis or vasodilatation [11], or a sustained 
increase in vascular permeability [16], and results in VEGFR2 degradation, not 
recycling [15]. It does, however, stimulate cytoprotection of endothelial and 
epithelial cells [17] and neurons [18]. These two isoform families, therefore, have 
very different physiological consequences [19], but any differential role in 
seasonal pituitary angiogenesis is unknown. We found that while total VEGF-A 
was not altered between the BS and NBS, there was a dramatic switch in splicing 
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in the BS from angiogenic VEGF-Axxxa isoforms to anti-angiogenic VEGF-Axxxb 
isoforms in both the PT and PD. This was mirrored by a reduction in the number 
of blood vessels in the infundibulum. Melatonin receptor expression in the PT and 
the infundibulum co-localized with cells expressing VEGF-A. Two potential 
mechanisms for VEGF-A-mediated regulation of pituitary seasonality are 
proposed here – a) VEGF-A acting to regulate blood vessel function, which 
subsequently controls delivery of other hormones to the PD, and b) VEGF-A 
acting directly on lactotrophs to control prolactin–associated down-regulation of 
the reproductive axis. We found that VEGFR2 co-localization with prolactin in the 
PD was increased outside the BS, consistent with a VEGF-Axxxa mediated 
repression of fertility. In vitro culture of PT cells from BS sheep showed that 
duration of melatonin exposure controlled VEGF-A isoform secretion – long 
exposure induced VEGF-Axxxb production, whereas short exposure induced 
VEGF-Axxxa production. Culture of PT cells from the NBS revealed that melatonin 
given at frequencies seen in the winter could switch the expression of VEGF-A 
isoforms to BS levels. We then showed that PT cells treated with NBS melatonin 
regimens release VEGF-Axxxa, which directly induced prolactin secretion from PD 
cells. Finally, the time-dependent, melatonin-induced differential expression of 
VEGF-A isoforms resulted in alterations of gonadotroph function opposite to 
those of lactotrophs in each season. Together, these results demonstrate that 
melatonin-mediated control of VEGF splicing could underlie intra-pituitary 
regulation of seasonal fertility.   
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Figure 1. Angiogenesis in the pituitary is seasonally dependent. A. Endothelial staining in the 
pars tuberalis (PT)/infundibulum and quantification of vessel loops in the summer (non-breeding 
season, NBS) and winter (breeding season, BS). B. Endothelial proliferation (PCNA/CD31 double 
positive cells) in the NBS and BS. C. Total VEGF-A levels in the PT/stalk in the BS and NBS (not 
significantly different; p>0.05). D. VEGF-Axxxb specific ELISA on protein extracted from 
pituitaries of animals killed in the BS or NBS. E. Proportion of VEGF-A that was VEGF-Axxxb in 
the BS and NBS. F. Staining of the melatonin receptor (green) and VEGF-A (red) in different 
regions of the pituitary; co-staining (found in PT and vascular loops) is shown as yellow.  ***= 




Vascular growth in the pituitary gland is seasonally controlled  
To investigate the vascular architecture of the pituitary in a seasonally breeding 
mammal, we screened pituitary glands of sheep with the endothelial marker 
CD31. Staining showed a significant (p<0.001) increase in the number of 
vascular loops extending from the PT into the infundibulum in the summer (non-
breeding season, NBS) compared with animals culled in the winter (breeding 
season, BS; Figure 1A). To determine whether this was due to endothelial 
proliferation in the NBS, we co-stained for CD31 and proliferating cell nuclear 
antigen, PCNA. We detected proliferating endothelial cells in both seasons, but a 
two-fold increase in proliferating endothelial cells in the NBS (Figure 1B). As 
angiogenesis is driven by VEGF, we measured VEGF-A in the pars-
tuberalis/stalk region of the pituitary. There was no difference in VEGF-A as 
measured by antibodies that detect all isoforms of VEGF-A (panVEGF; Figure 
Angiogenesis dependent seasonal control of pituitary function  
 
 9 
1C). However, using antibodies that specifically detect the exon 8b splice 
variants (VEGF-Axxxb), the expression of which has been shown to be anti-
angiogenic in vivo, a reduction in VEGF-Axxxb was measured in the NBS (Figure 
1D). This resulted in a change in the ratio of VEGF-A from 33% excess anti-
angiogenic isoforms in the BS, to 60% excess angiogenic isoforms in the NBS 
(Figure 1E). This indicates that the pituitary is in an anti-angiogenic state in the 
BS, and suggests a link between day length and VEGF-A splicing. To determine 
whether VEGF-A was expressed in the pituitary in cells that can respond to day 
length, we co-stained for melatonin receptor and VEGF. Figure 1F shows that 
MT1 and VEGF-A were co-localized in the PT and, interestingly, also in the 
vascular loops (arrows) that connect the PT with the infundibulum. In contrast, 
while VEGF-A was expressed in the PD, MT1 receptors were not. The anti-
angiogenic isoforms have not previously been cloned from sheep, so we 
examined RNA expression by RT-PCR. Both isoforms were detected in 
pituitaries from sheep in both seasons (PD and PT, supplementary Figure 1A). 
Cloning and sequencing of the PCR product confirmed that this was sheep 
VEGF-Axxxb (supplementary Figure 1B). The sheep sequence has a single 
nucleotide substitution (a G in sheep, C in human) compared with human DNA. 
This results in a single amino acid difference, with a sequence of SRTRKD 
instead of SLTRKD in human. Thus, the sheep VEGF-Axxxb isoforms are one 
amino acid shorter than the human ones. The cell type in which VEGF-Axxxb was 
expressed in the PT was identified by immunolocalization. Supplementary Figure 
1C confirms that VEGF-Axxxb is expressed in the MT1 positive cells, which, in the 
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PT, are not endothelial or glial-type folliculostellate (S100+) cells. These results 
suggested that melatonin could regulate expression of different VEGF-A isoforms 
in the PT, so regulating angiogenesis in the pituitary in a seasonally dependent 
manner. 
 
VEGF-A splicing is regulated by duration of melatonin exposure in PT cells 
We investigated VEGF-A isoform expression in cells isolated from the PT, which 
express both the melatonin receptor and VEGF-A (supplementary Figure 2A) by 
isoform family specific ELISA and real time PCR. Cells were cultured under 
conditions without melatonin (control, supplementary Figure 2B) or with 
melatonin given for 16hrs (mimicking winter –BS regimen), or 8 hours (mimicking 
summer –NBS regimen). VEGF-Axxxb protein (Figure 2A) was increased 7 fold by 
a BS melatonin regimen (Figure 2A) in cells from BS animals (i.e. given the 
matching melatonin regimen), whereas panVEGF-A increased only 4 fold (Figure 
2B). In contrast, when cells from pituitaries of NBS sheep were given the NBS 
melatonin regimen, VEGF-Axxxb was only increased 2-fold (significantly lower 
than BS, Figure 2A), but panVEGF-A was increased 5-fold (Figure 2B), although 
this response took longer than in the BS cells. This suggests that the length of 
time that the cells are daily exposed to melatonin controls the expression of the 
different splice variants of VEGF-A. It also suggests that NBS cells are less 
prepared to respond to melatonin exposure, as they take longer to increase their 
VEGF-Axxxa output. To determine whether this was dependent on the stage of 
the annual reproductive cycle, we treated cells with a melatonin regimen that was 
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reversed (i.e. opposite to that of the prevailing photoperiod) and found the same 
response for VEGF-Axxxb - BS regimen induced VEGF-Axxxb expression, whereas 
NBS regimen did not (Figure 2C). The same was true for panVEGF-A (Figure 
2D) – expression was induced by both regimens, but NBS cells were slower to 
respond than BS cells. To confirm that this was due to a change in the RNA 
splice isoforms, we measured RNA levels of VEGF-A164b and VEGF-A1654a by 
quantitative RT-PCR using isoform specific primers. Figure 2E shows that VEGF-
A164a and VEGF-A164b were preferentially upregulated by the NBS and BS 
regimens, respectively, in BS cells. In NBS cells, the same effect was induced by 
switching the melatonin regimen, indicating that this effect is specific to the 
duration of melatonin exposure, rather than the stage of the annual reproductive 
cycle from which the cell was sourced. These results indicate that melatonin can 
control angiogenesis protein production in the PT. 
 
VEGF-A splice isoforms and receptors are present in the PD 
To determine whether VEGF-A could target endocrine and /or non-endocrine 
cells that are known to display seasonal plasticity, we screened the PD for the 
VEGF receptor, VEGFR2. Co-staining of VEGFR2 with folliculostellate cells 
(FSC, Figure 3A) and lactotrophs (LT, Figure 3B) showed that VEGFR2 was co-
localized with a proportion of FSC and LT, and critically, that this co-localization 
increased (p<0.01 and p<0.001, respectively) during the non-breeding season 
(NBS), i.e. in the summer. There was also substantial VEGFR2 expression co-
localized on endothelial cells in both seasons (Figure 3C). Screening for 
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proliferating endothelial cells indicated that there was more angiogenesis in the 
summer (NBS) in the PD (Figure 3D), as well as the PT and infundibular stalk 
(Figure 1D). Immunofluorescence staining for VEGF-A isoforms indicated that 
VEGF-Axxxb was significantly down-regulated and VEGF-Axxxa significantly up-
regulated in the summer (NBS, Figure 3E), providing a rationale for the up-
regulation of angiogenesis in the PD. Quantification of the area of staining 
(Figure 3F) confirmed this finding, as did quantitative ELISA for VEGF-Axxxb 
(down-regulation in the summer –NBS; Figure 3G) and panVEGF-A (Figure 3H – 
no change – and hence an implied up-regulation of angiogenic isoforms in the 
NBS). 
 
VEGF-A isoforms control seasonal endocrine function 
These results lead to two hypotheses: a) that VEGF-A controls angiogenesis and 
this allows, by increased portal blood flow, an as yet unidentified compound to 
repress the reproductive axis (presumably, at least in part, by stimulating 
prolactin); and/or b) that VEGF-A itself is a signalling molecule from the PT to the 
PD, which directly contributes to the inhibitory regulation of the reproductive cycle 
by releasing prolactin. To test this latter hypothesis, we cultured PD cells from 
sheep in the NBS or BS and treated them with recombinant human VEGF-A165a 
(rhVEGF-A165a) or conditioned media from the PT cells taken at the same time of 
year, and measured prolactin production by radioimmunoassay. Figure 4A shows 
that VEGFR2 and prolactin were both expressed by PD cells in culture. Figure 4B 
shows that the cells from both NBS and BS animals could be induced to release 
Angiogenesis dependent seasonal control of pituitary function  
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prolactin by thyrotropin-releasing hormone (TRH), but not by melatonin. Figure 
4C shows that rhVEGF-A165a, given for the duration that matches NBS melatonin 
exposure (i.e. 8 hrs in the summer), resulted in significant prolactin release from 
PD cells from NBS animals (p<0.001), and from cells from the BS 
(supplementary Figure 3A). It also showed that rhVEGF-A165a, given at BS 
duration (16 hours) did not cause prolactin release from BS (Figure 4C) or NBS 
cells (supplementary Figure 3A). We confirmed this at the RNA level (Figure 4D-
E). To determine whether PT cells could generate VEGF-A isoform ratios that 
induced prolactin, we took conditioned media from the PT cells treated with 
melatonin and treated the PD cells with this conditioned media to mimic the in 
vivo situation. Conditioned media from PT cells treated with NBS melatonin 
regimen significantly stimulated prolactin protein (Figure 4F) and mRNA (Figure 
4G) in cells from non-breeding season ewes, but did not result in FSH production 
(supplementary Figure 3B). Critically, this effect was completely blocked by an 
antibody to VEGF-Axxxa (Figure 4F, G). Conditioned media from PT cells treated 
with BS melatonin regimen had no effect on prolactin production from breeding 
season PD cells (Figure 4F), but did stimulate FSH mRNA production from these 
cells (supplementary Figure 3C), and from cells from non breeding season ewes 
(supplementary Figure 3D), an effect which was inhibited by pre-treatment with a 
VEGF-Axxxb specific antibody (supplementary Figure 3D). This indicates that 
melatonin duration-induced differential VEGF-A isoform production by the PT has 
the potential to regulate the seasonal production of prolactin and FSH by the PD 
through an intra-pituitary paracrine mechanism mediated by VEGF. 
Angiogenesis dependent seasonal control of pituitary function  
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Figure 2. VEGF-A isoforms levels are regulated by melatonin periodicity in the PT. A. PT 
cells in culture were isolated from pituitaries of sheep and VEGF-Axxxb measured by ELISA. 
Cells from winter sheep (breeding season -BS, blue) were treated with melatonin for 16 hrs each 
day for 6 days; cells from summer sheep (non-breeding season –NBS, red) were treated for 8hrs 
each day with melatonin. B. Levels of panVEGF-A were also measured from these cells. C. 
VEGF-Axxxb levels were measured from sheep PT cells incubated with the incongruous 
melatonin exposure for the time they were harvested from (cells from summer sheep were given 
winter a melatonin regimen, and from winter sheep given a summer melatonin regimen). D. 
Levels of panVEGF-A from cells treated as in C. E. VEGF-A isoform mRNA expression in PT 
cells from the breeding season (BS, winter) after 6 days of treatment with BS and NBS melatonin 
regimens. F. VEGF-A isoform mRNA expression in PT cells from the non-breeding season (NBS, 
summer) after 6 days of treatment with BS and NBS melatonin regimens. Boxes show positions 
of the primers used to amplify the cDNA. ***= p<0.001 compared with Control, +++= p<0.001 





The rationale for these studies was that dynamic and tightly regulated changes in 
the vascular communication between the brain and the pituitary gland could 
underlie seasonal physiology. To that end, we used a highly seasonal animal 
model, the sheep, with a well-characterized annual reproductive cycle. The 
results show that the pituitary microvasculature that connects the PT with the 
neural tissue of the infundibulum, before contacting the PD, displays dramatic 
seasonal remodelling, and that this could be in response to locally regulated 
splice variants of VEGF-A in the photoperiodic responsive / melatonin sensitive 
Angiogenesis dependent seasonal control of pituitary function  
 
 15 
PT region. Importantly, we found that the melatonin-induced differential 
expression of VEGF-A isoforms in the PT throughout the annual reproductive 
cycle not only has the potential to alter the portal microvasculature, but that itself 
could operate as a messenger to modify the endocrine output from the PD. We 
established that the signal from the PT carried to hormone-producing cells in the 
PD to stimulate prolactin secretion and inhibit FSH during reproductive 
quiescence is the angiogenic isoform of VEGF, VEGF-A164. Moreover, the results 
reveal that the splicing of the VEGF-A pre-RNA from anti-angiogenic VEGF-A164b 
in the winter (BS) to pro-angiogenic VEGF-A164a in the summer (NBS) results 
from the different duration of melatonin exposure, which occurs across seasons, 
highlighting the existence of a previously unknown photoperiodically-regulated 
system for the seasonal control of fertility.  
 
Figure 3. VEGFR2 is upregulated in the PD during the summer (non-breeding season). A. 
Co-localization of VEGFR2 (green) and glial-type folliculostellate cells (red) in the breeding 
season (BS, winter) and non-breeding season (NBS, summer). B. VEGFR2 (green) expression in 
lactotrophs (red) in the BS and NBS. C. VEGFR2 (green) and endothelial cells stained by 
isolectinB4 (IB4, red) in both seasons. D. Proliferating (PCNS, green) endothelial (IB4, red) cells 
were stained, and co-localization quantified. E. VEGF-Axxxb expression detected in the PD in the 
winter (BS), but not in the summer (NBS); VEGF-Axxx expression detected in the summer (NBS) 
but not in the winter (BS). F. Quantification of the expression of VEGF-A isoforms. G. ELISA 
quantification of the amount of VEGF-Axxxb in the BS and NBS. H. ELISA quantification of the 
amount of total VEGF-A in the two seasons. *= p<0.05, **= p<0.01, and ns= non-significant 
(p>0.05) compared with BS. Scale bar = 50µm 
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The microvasculature of the pituitary gland is key to the regulation of multiple 
body functions because it controls the blood flow from the hypothalamus, altering 
the delivery of stimulatory and inhibitory signals to endocrine target cells [20]. 
Here we show that this vascular connection undergoes a remarkable seasonal 
adaptation throughout the annual reproductive cycle in response to an external 
cue, namely the changing photoperiod. Such vascular plasticity is manifested in 
alterations of endothelial cell proliferation that result in timely changes in the 
vascular loops that connect the PT with the infundibulum before giving rise to the 
long portal vessels which terminate in the PD. Even though these loops were first 
described over six decades ago [21], the possibility that they could alter the 
connectivity between the brain and the pituitary at certain times of the year was 
not known. Although no apparent alterations in the ovine pituitary vasculature of 
male castrates exposed to different photoperiods was recently reported, detailed 
measurements were not undertaken and the vascular loops were not specifically 
examined [22]. The increased number and surface area of these vascular loops 
during the long days of the NBS, concomitant with an increase in endothelial cell 
proliferation, is in agreement with the increased number of cells proliferating in 
the PT shown in this study and by another group [23] at this time of year.  
 
Figure 4. VEGF-A mediates prolactin release from the PD in an isoform dependent manner. 
A. VEGFR2 expression in cultured prolactin positive cells (lactotrophs) of the PD. B. Prolactin 
secretion following treatment with thyrotropin-releasing hormone (TRH, positive control), 
melatonin (Mel, negative control) and medium (control) in PD cells cultured during the non-
breeding season (NBS, summer) and breeding season (BS, winter). C. Prolactin secretion in PD 
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cells from sheep killed in the summer (NBS) after rhVEGF-A165a treatment was greater than that 
from winter (BS) sheep. D. Prolactin mRNA expression in PD cells taken from ewes in the 
summer (NBS) following a summer (NBS) regimen of rhVEGF-A165a (8hrs on, 16hrs off), was 
greater than that of cells taken from the same animals following a winter (BS) rhVEGF-A165a 
regimen (16hrs on, 8hrs off). E In cells taken from ewes in the breeding season (BS, winter), 
prolactin was only induced if VEGF-A was given in a non-breeding season (NBS, summer) 
regimen, F. Conditioned media from summer (NBS) PT cells treated with a summer (NBS) 
melatonin regimen (red) induced prolactin production. This was blocked by an antibody to VEGF-
Axxxa. G. Prolactin mRNA in summer (NBS) cells was induced in the presence of conditioned 
media from summer (NBS) regimen PT cells, and this was blocked by an anti-VEGF-Axxxa 
antibody. **=p<0.01, ***=p<0.001 compared with BS. Scale bar = 20µm 
 
The afferent branches of these loops connect the photoperiodic-responsive PT 
with the FS cell-rich infundibulum, and efferent branches provide communication 
between the infundibulum and the PD where most of the pituitary hormones are 
produced. Thus, the temporal remodelling of the vascular connection between 
these three tissues highlights the existence of a control point for seasonal 
physiology. The importance of this finding is supported by recent studies in 
rodents showing that the pituitary microvasculature adapts to the needs of 
pituitary endocrine cells and that it can control endocrine output according to the 
physiological requirement of the individual [24]. This remodelling could 
substantially increase or decrease the transport of hormones from the PT to the 
infundibulum and from the infundibulum to the PD, thus being able to accentuate 
or reduce the effect of hypothalamic derived neuroendocrine signals, such as 
GnRH, to the hormone producing cells of the pituitary.  It is possible that this 
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regulatory mechanism for the delivery of hypothalamic factors could operate in 
conjunction with the dynamic retraction / protraction of ‘endfeet’ processes of 
tanycytes [25], the specialized ependymal cells of the glia, which have been 
shown to interact with the hypothalamic neuronal terminals and fenestrated 
capillaries of the median eminence and to play a role in the control of the 
seasonal reproductive cycle in birds [26]. The VEGF isoforms have been shown 
to differentially regulate fenestrations of endothelial cells [16], so it is possible 
that the two mechansims could work together, although we are unable to use the 
evidence presented here to differntiate between dependnet and independent 
mechanisms. 
 
In other tissues, vascular remodelling and permeability is controlled by VEGF-A 
[19], so dynamic changes in the pituitary microvasculature were expected to 
correspond to alterations in VEGF-A expression. Indeed, VEGF-A-mediated 
changes in endothelial cell proliferation and angiogenesis were communicated in 
specific regions of the songbird brain across seasons [27]. However, VEGF-A 
had been previously reported to remain unchanged in the pituitary of sheep 
under different photoperiods [28], and in this study panVEGF-A expression did 
not differ between BS and NBS animals. Critically, the use of specific antibodies 
to the pro- and anti-angiogenic isoforms of VEGF-A (these distinguish between 
isoform families, but not between the different length isoforms, hence VEGF-
Axxxa  and VEGF-Axxxb) revealed differential isoform expression between the long 
days of the NBS and the short days of the BS, with over-expression of anti-
Angiogenesis dependent seasonal control of pituitary function  
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angiogenic VEGF-Axxxb variants in the BS, and increased expression of pro-
angiogenic VEGF-Axxxa variants in the NBS, providing an explanation for the 
observed changes in the microvasculature. As the PT is the tissue with the 
highest density of melatonin receptors [4, 5], and reliably translates the effects of 
photoperiod on circadian and circannual physiology within the pituitary [1, 29], 
our results showing the co-expression of VEGF-A and melatonin receptors in PT-
specific cells provide compelling evidence that the seasonal regulation of the 
vascular connection between the brain and the pituitary gland is mediated by a 
melatonin-induced mechanism within the PT region that leads to differential 
expression of pro- and anti-angiogenic VEGF-A isoforms. Moreover, our results 
show that in addition to the PT-specific cells, melatonin could also act directly on 
the vascular loops, revealing a previously unknown target for melatonin action to 
translate photoperiodic effects on seasonal physiology.  As the blood flows from 
the brain to the pituitary [11], alterations in the vascular loops of the infundibulum 
that will give rise to the long portal vessels [12] could contribute not only to 
regulate the transfer of PT products to the PD, but also to alter the delivery of 
hypothalamic factors; thus, the increased vascular connections during the long 
days of summer would be expected to favor increased supply of stimulatory and 
inhibitory hypothalamic signals to the PD at this time of year. Notwithstanding, 
the reduction in vascularity during the short days of winter is likely to play a role 
in the modulation of the gonadotroph response to GnRH, by means of preventing 
desensitization of GnRH receptors [30], and fine-tuning the differential control of 
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gonadotropin secretion [31, 32], which are essential processes to ensure normal 
fertility.  
 
Photoperiodic information is encoded by the duration of nocturnal melatonin 
secretion [2], so we employed a paradigm where ovine PT cells were cultured 
and daily exposed to summer (NBS) or winter (BS) durations of melatonin 
treatments (8 vs. 16h, respectively) over a period of six days. PT cells from the 
same animals were exposed to both the matching and non-matching (i.e. 
opposite season) melatonin regimens, so we were able to differentiate direct 
effects of the melatonin signal and those resulting from its interaction with the 
circannual phase. We show that duration of melatonin exposure induced a 
striking differential expression of VEGF-A isoforms, with up-regulation of the pro-
angiogenic isoform VEGF-Axxxa by a short duration (i.e. 8h, summer; NBS) 
regimen, and up-regulation of the anti-angiogenic isoform VEGF-Axxxb by a long 
duration (i.e. 16h, winter; BS) regimen. This melatonin duration-dependent 
differential expression of VEGF-A isoforms was also recorded in cells obtained in 
the opposite season but at a slower rate, highlighting the requirement of PT cells 
to be entrained to the new signal. Thus, the results are consistent with the 
findings ex-vivo and demonstrate that pituitary micro-vascular remodelling is 
likely to be sensitive to the changing photoperiod and adapts to the physiological 
requirements of the animal in response to time-dependent melatonin signals 
acting on VEGF-A.  The mechanism through which melatonin switches splicing of 
the VEGF-A gene is not yet known, but alternative splicing of VEGF has been 
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shown to be regulated by activation of the RNA binding proteins SRSF1, SRSF2 
and SRSF6 by the kinases SRPK1 and Clk4 [33].  
 
We then investigated whether the seasonal regulation of VEGF-A in the PT could 
affect the function of the PD. We show that VEGF-A receptors are expressed in 
endocrine, endothelial and FS cells in the PD and that their co-localization is also 
under seasonal control, with up-regulation during the long days of the NBS. In 
addition, there was increased content of pro-angiogenic VEGF-A isoforms at this 
time of year and, conversely, increased content of the anti-angiogenic isoforms 
during the short days of the BS. Since the seasonal regulation of VEGF-A 
isoform expression was shown to be melatonin-dependent and, in accordance 
with previous studies [34], the PD was shown not to contain melatonin receptors, 
the varying content of VEGF-A isoforms in the PD is likely to rely on a paracrine 
mechanism [35]. The physiological significance of this was first revealed in the 
PD microvasculature, with increased endothelial cell proliferation demonstrated 
during the NBS. We show that this increase in angiogenesis at this time of the 
annual reproductive cycle is concomitant with an increase in the prevalence of 
FS cells containing VEGF receptors. FS cells are glial-like, non-endocrine cells 
that, via gap-junctions, generate a three-dimensional network throughout the 
pituitary to coordinate its function [36, 37]. These cells secrete an array of 
paracrine factors known to influence endocrine cells such as gonadotrophs and 
lactotrophs, and are a primary source of VEGF-A [35]. In seasonal breeders, FS 
cells are distributed throughout the PD and PT [38] and respond to photoperiodic 
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changes with a high degree of plasticity [39, 40]. In sheep, significant ultra-
structural changes together with enhanced number of intercellular adherens 
junctions and increased number of elongated processes surrounding endocrine 
cell clusters were reported during the long days of the NBS [41]. As FS cells do 
not contain melatonin receptors [42], our findings revealing up-regulation of 
VEGF receptor content in these cells at this time of year provide evidence for a 
role of VEGF-A in the dynamic changes of the FS cell network to control vascular 
plasticity via the regulation of its own production during the annual reproductive 
cycle. The seasonally regulated differential expression of VEGF-A isoforms in the 
pituitary gland of a short day breeder unravelled here, could also operate in long 
day breeders, such as hamsters and horses, as part of the mechanisms 
controlling their annual physiology. Indeed, preliminary results have provided 
evidence that, in Thoroughbred horses, VEGF-A isoform expression in both, the 
PT and PD regions of the pituitary, is also seasonally regulated [43], suggesting 
that this is a conserved mechanism for seasonal adaptation in photoperiodic 
mammals.  
 
Notably, we show that, in addition to its actions on the pituitary vasculature and 
FS cell population, VEGF-A has a potent prolactin releasing effect, and that this 
stimulation depends on time of exposure of the ligand and density of VEGF 
receptors in lactotrophs, which is increased during the long days of the NBS. 
Moreover, these stimulatory effects of VEGF-A on prolactin synthesis and 
release were accompanied by suppression of the gonadotrophic axis, as 
Angiogenesis dependent seasonal control of pituitary function  
 
 23 
revealed by inhibition of FSH gene expression. Melatonin was shown to mediate 
the photoperiodic regulation of prolactin secretion through a direct action within 
the pituitary gland [6]. Because MT1 melatonin receptors are selectively 
expressed in the PT, and this region is deprived of lactotroph cells [7, 8], a 
paracrine mechanism for the control of prolactin secretion from the PD is 
warranted. Activation of MT1 melatonin receptors in the PT is known to inhibit 
adenylyl cyclase, and pharmacological studies in sheep have shown that 
melatonin impairs forskolin-induced hypersecretion of cyclic adenosine 
monophosphate (cAMP), with inhibition of prolactin from the PD through the 
reduction of a paracrine signal [44]. However, although several compounds such 
as tachykinins, substance P and neurokinin A are produced by the PT and can 
stimulate prolactin release [45-47], characterization of the chemical identity of 
that signal has been elusive. Here we show that the stimulatory effects of VEGF-
A on prolactin were mimicked by conditioned media from PT cultures exposed to 
a NBS regimen of melatonin, and that these actions of PT media were blocked by 
a specific VEGF-Axxxa antibody, demonstrating that VEGF-A is a potential 
paracrine signal, and that melatonin-induced differential VEGF-A isoform 
production by the PT can regulate the seasonal production of both prolactin and 
FSH. Because these effects were also recorded in PD cells obtained in the 
opposite season (i.e. BS), albeit with a three-day lag required for adaptation, our 
results show that the photoperiodically-induced paracrine mechanism mediated 
by VEGF-A can ultimately override the circannual phase of the PD target cells, 
and entrain it to the new photoperiod. The increased VEGF receptor content in 
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the PD during the NBS plays a major role in mediating this process, and thus in 
the biological adaptation to a summer physiology, because VEGF-A treatments 
mimicking a NBS melatonin regimen showed a delayed response in BS cultures 
where the VEGF receptor content was reduced.  
 
Figure 5. Working model for a melatonin-induced, VEGF-A isoform dependent intra-pituitary 
regulation of seasonal physiology. In this model, the duration of nocturnal melatonin secretion 
induces differential synthesis and release of pro-angiogenic and anti-angiogenic isoforms of 
VEGF-A in the PT region of the ovine pituitary and in the vascular loops that connect this tissue 
with the infundibulum. A. In the short days of winter (BS), the long duration of nocturnal melatonin 
exposure up-regulates the secretion of the anti-angiogenic isoform VEGF-A164b at the expense 
of the pro-angiogenic isoform VEGF-A164a, resulting in reduced angiogenesis, reduced density 
of VEGF receptors in endocrine and FS cells of the PD, suppression of prolactin secretion and no 
inhibition of the gonadotrophic axis. B. In contrast, during the long days of summer (NBS), the 
short duration of nocturnal melatonin exposure up-regulates the secretion of the pro-angiogenic 
isoform VEGF-A164a at the expense of the anti-angiogenic isoform VEGF-A164b, leading to 
increased angiogenesis, increased density of VEGF receptors in endocrine and FS cells of the 
PD, stimulation of prolactin secretion and inhibition of the gonadotrophic axis. 
 
Entrainment of the PD cells to a specific phase of the circannual cycle explains 
why NBS cells failed to secrete prolactin in response to the first 8 hours of either 
a BS (16 h) VEGF-A regimen, or PT conditioned media from the BS. 
 
In rodents, melatonin-induced suppression of cAMP is followed by sensitization 
of adenosine A2b receptor signalling, leading to subsequent increase in cAMP 
and CREB phosphorylation [28]. Disruption of this signalling pathway in MT1 
Angiogenesis dependent seasonal control of pituitary function  
 
 25 
melatonin receptor knock out mice resulted in altered prolactin secretion, 
implicating cAMP and adenosine in this biological response to melatonin. Our 
results indicate that VEGF-A is likely to be downstream of that pathway to bring 
about the biological response. Indeed, cAMP signalling, CREB phosphorylation 
and adenosine are associated with angiogenesis [48, 49] via stimulation of 
VEGF-A [50], and whereas pharmacologically induced cAMP up-regulation and 
treatment with adenosine stimulated VEGF-A expression in smooth muscle cells 
[50], the selective knockdown of all VEGF-A isoforms blocked the actions of 
elevated cAMP on hippocampal neurons [51]. The melatonin induced VEGF-A 
regulation of prolactin secretion shown in this study will have an impact on the 
gonadotrophic axis in addition to its direct inhibition of FSH, because when 
combined with dopamine prolactin impairs the gonadotroph response to GnRH in 
a seasonal dependent manner in both long and short day breeders [52-54].  
 
Our results provide evidence for an intra-pituitary mechanism that responds to an 
external independent signal to regulate seasonal physiology. We propose a 
model where the duration of nocturnal melatonin secretion promotes alternative 
splicing of the VEGF-A gene leading to differential synthesis and release of pro-
angiogenic and anti-angiogenic isoforms of VEGF-A within the PT region of the 
pituitary gland and in the vascular loops that connect this tissue with the 
infundibulum (Figure 5). The resulting output of VEGF-A isoforms will have two 
complementary effects: 1) it alters the temporal vascular connection between the 
brain and the pituitary gland; and 2) it can be used as a paracrine signal to 
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modify the seasonal activity of endocrine cells in the PD that control reproduction. 
In this model, the long duration of nocturnal melatonin exposure during the winter 
up-regulates the secretion of anti-angiogenic isoforms VEGF-Axxxb at the 
expense of pro-angiogenic isoforms VEGF-Axxxa, resulting in reduced 
angiogenesis, reduced density of VEGF receptors in endocrine and FS cells, 
suppression of prolactin secretion and no inhibition of the gonadotrophic axis 
characteristic of the BS. Conversely, the short duration of nocturnal melatonin 
exposure during the summer will up-regulate the secretion of pro-angiogenic 
isoforms VEGF-Axxxa at the expense of anti-angiogenic isoforms VEGF-Axxxb, 
leading to increased angiogenesis, increased density of VEGF receptors in 
endocrine and FS cells, stimulation of prolactin secretion and inhibition of the 
gonadotrophic axis, characteristic of the NBS. Thus, the model permits a 
physiological adaptation to the seasonal requirements of the species by means of 
an angiogenesis dependent intercommunication between two regions of the 
pituitary.   
 
Materials and Methods 
Details of standard protocols are given in the supplementary materials. Ovine 
pituitary glands were obtained from ovary-intact females during the breeding 
season (BS -December ⁄January) and the non-breeding season (NBS -June 
⁄July). Animals were killed for commercial reasons at an abattoir and pituitaries 
removed immediately after death. During the BS, ewes were confirmed to be 
sexually active on the basis of a recently formed corpus luteum (CL) together 
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with the presence of a large follicle (> 2 cm). By contrast, in the NBS, ewes were 
considered to be anestrus when no CL but a corpus albicans was observed in the 
gonad, and follicles present were < 2 mm diameter.  
Expression studies 
Pituitaries were stained and RNA was extracted [55] using standard procedures 
(details of antibodies in supplementary Tables 1-2 and primers shown in 
supplementary Table 3). The term VEGF-Axxxb is used as the antibodies do not 
distinguish between the different VEGF-Axxxb isoforms (e.g. VEGF-A121b, VEGF-
A165b, VEGF-A189b). The term VEGF-A164b or VEGF-A165b is used when the 
methodology specifically describes the sheep 164 amino acid isoform (isoform 
specific RT-PCR, as the forward primers cross Exon 5 and Exon 7), or the 
human 165 amino acid isoform when recombinant protein is used). 
 
Primary cell cultures  
Ovine primary pituitary cultures were produced by careful dissection and 
dissociation of the pars distalis (PD) and pars tuberalis (PT) of 3-4 pituitaries as 
previously described 52. Previous studies have demonstrated the validity of this 
method for producing a reliable hormone output in response to exogenous 
hormone releasing secretagogues in vitro [52, 56].  
Both ELISA methods have been previously described [57-58,11]. A rhVEGF165b 
positive control was included in triplicate for the human VEGF-A ELISA, allowing 
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calculation of VEGF-Atotal concentration to compensate for reduced VEGF-Axxxb 
affinity, approximately 42%, as previously published [59]. Prolactin was 
measured by RIA using purified ovine prolactin for standards. A linear 
relationship was detected when the measured hormone concentration (ng ⁄ ml) 
was plotted against the concentration of diluted serum samples.  
Statistical analysis  
In both the BS and NBS cultures, a total of five separate experimental treatments 
were applied to PT cells, and nine experimental treatments applied to the PD 
cells. For each treatment, six wells were assigned, and the experiments were 
repeated independently three times in both seasons with reproducible results. 
The reported values represent the mean +/-SEM. The effects of season, 
experimental treatment and their interaction on the secretion VEGF-A and 
prolactin from ovine primary pituitary cell cultures were examined using ANOVA 
followed by Fisher’s post-hoc test. Because a season by treatment interaction 
was observed for each compound, separate ANOVAS were then used to 
examine the effects of experimental treatment within season. For all other 
variables one-way ANOVA was applied. All data were confirmed to be normally 
distributed by D’Agostino and Pearson omnibus normality test. Data were 
considered to be statistically significant when p<0.05; however, wherever 
detected, smaller log value (p<0.01, p<0.001) probabilities are reported.   
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S1 Materials and Methods 
 
EXPERIMENTAL PROCEDURES 
Ovine pituitary glands were obtained from ovary-intact females during the 
breeding season (BS -December ⁄January) and the non-breeding season (NBS -
June ⁄July). Animals were killed for commercial reasons at an abattoir (University 
of Bristol Abattoir, Langford, UK) and pituitaries removed immediately after death. 
During the BS, ewes were confirmed to be sexually active on the basis of a 
recently formed corpus luteum (CL) together with the presence of a large follicle 
(> 2 cm). By contrast, in the NBS, ewes were considered to be anestrus when no 
CL but a corpus albicans was observed in the gonad, and follicles present were < 
2 mm diameter.  
Immuno-fluorescent staining 
Pituitaries assigned for immunofluorescent staining (BS n = 6; NBS n =6) were 
fixed in Bouin’s solution for 24 hrs and then moved to 70% ethanol, and 
sectioned at 5m. Following sequential dehydration, sections were submerged in 
PBS-T (0.1% Triton-X) and then 0.01M sodium citrate buffer (pH6; Sigma) and 
heated for 3 min at full power, and 12 min at sub-boiling temperature. Sections 
were then washed in PBS-T (3 x 5 min), and blocked in 5% goat serum diluted in 
1% BSA PBS-T (0.01%) for 2 hrs at RT. A range of primary antibodies were used 
for double florescent immunohistochemistry (IMF), each diluted to a 
concentration determined during preliminary investigations (Table 1). Secondary 
antibodies were diluted as outlined in Table 2 and left to incubate on the section 
for 2 hrs at RT. 
cDNA synthesis and RT-PCR and RT-qPCR 
Pituitaries assigned for DNA analysis of VEGF-A expression were flash-frozen in 
liquid nitrogen following dissection. RNA Extraction was carried out by TRI 
reagent method, itself a modification from the original phenol/chloroform 
extraction developed by Chomczynski et al. [60]. Multiple pairs of primers were 
used to amplify the various VEGF-A isoforms (Table 3). To generate cDNA, 2μg 
of RNA and 2 units of RNase-Free DNase (RQ1, M6101, Promega) were 
incubated in a 1x reaction buffer solution for 1 hour at 37°C, before 1μl of DNase 
stop solution was added to terminate the reaction, and the sample was heat 
inactivated for 10 minutes at 65°C. The DNase-treated RNA sample was re-
quantified by using a Nanodrop ND-1000 spectrophotometer and 1μg of RNA 
was re-suspended to a total volume of 10μl. To this, 2μl of Oligo (dT)15 primers 
(C1101, Promega) and 1μl of hexamers (Random Primers, C1181, Promega) 
were added. The reaction mix was then incubated at 70°C for 10 minutes before 
immediately being quenched on ice for 5 minutes. With a final reverse 
Angiogenesis dependent seasonal control of pituitary function  
 
 2 
transcription reaction volume of 50μl, 400 units of MMLV reverse transcriptase 
(M5301, Promega), 40 units of RNasin ribonuclease inhibitor (N2611, Promega) 
and 0.5mM dNTPs (BIO-39049, Bioline) were added to the RNA/primer mix. The 
reaction was incubated for 1.5 hours at 37°C with a final 70°C inactivation step. 
Final concentration of fresh cDNA was determined by spectrophotometry. 
For RT-PCR, forward and reverse primer (1μM, see Table 3) were added each 
with 1.2mM MgCl2, 200μM deoxynucletide triphosphates, and 1 unit of Taq 
polymerase (Abgene, Thermo-Fischer, Epsom, UK). PCR was undertaken for 35 
cycles, at 95°C for 1 min, 60°C for 5 mins and 72°C for 5 mins with a 2 minute 
95°C denaturing step at the beginning and a 72°C extension step at the end. 
PCR products were run on 3% agarose gels containing 0.5 μg/ml Ethidium 
Bromide and visualized under a UV transilluminator.  For RT-qPCR, cDNA was 
added to 5.5μl of SYBRG fast track with Rox (Kappa Biosystems, Wilmington, 
Massachusetts, USA), 1µM of each primer in a total of 18µl. Samples were 
loaded in triplicate and a negative control of water was added. GAPDH was used 
as a reference gene. 
Primary cell cultures  
Ovine primary pituitary cultures were produced using a method previously 
described [61]. Briefly, the pars distalis (PD) and pars tuberalis (PT) of 3-4 
pituitaries were carefully dissected and incubated in a 0.1% collagenase D 
(Boehringer Mannheim, Mannheim, Germany) and hyaluronidase (Sigma-Aldrich, 
Poole, UK) solution in a shaking water bath at 37 °C for 75 min. The tissue was 
then manually dispersed in phosphate-buffered saline (Sigma-Aldrich) and the 
mixed pituitary cells re-suspended in M199 medium (Invitrogen, Paisley, UK) 
containing 10 mg ⁄ ml of insulin, 50 mg ⁄ ml of gentamicin, 100 IU ⁄ ml of penicillin-
streptomycin (Sigma-Aldrich) and 10% steroid-free lamb serum (Invitrogen), 
before being plated at a density of 200 000 cells ⁄ well in 24-well plates. The 
experiment was repeated three times each in the BS and NBS, totalling 9-12 
animals per season. During both the BS and the NBS, cells were maintained in 
culture for 6 days. M199 media was changed at each time point outlined below. 
Previous studies have demonstrated the validity of this method for producing a 
reliable hormone output in response to exogenous hormone releasing 
secretagogues in vitro [61, 62].  
PT cells were assigned one of the following treatments; i) Control - M199 media 
alone, changed daily at 5pm and 9am; ii) BS regimen – melatonin (1µM), 
administered at 5pm, removed at 9am, media alone administered from 9am until 
5pm; iii) NBS regimen - melatonin administered at 9pm, removed at 5am, media 
from 5am until 9pm. Three experimental groups of PT cells per season were 
used. Six wells were assigned per treatment, 3 wells used for RNA based 
assays, and 3 wells for protein based assays. In one repeat of each experiment 
per season, 1 well per treatment was used for IMF. PD cells were treated with the 
following treatments: i) Control (C) – M199 media alone, changed every day at 
5pm and 9am; ii) BS regimen - recombinant human VEGF-A165a  (1nM rh.VEGF-
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A165a  ), or 1µM melatonin, or 0.1µM thyrotropin releasing hormone (TRH), or 
conditioned media from PT cells treated as above  administered at 5pm, removed 
at 9am, and media alone administered from 9am until 5pm; iii) NBS regimen 
rh.VEGF-A165a  melatonin, or TRH, or conditioned media from PT cells treated as 
above, administered at 9pm, removed at 5am, media alone administered from 
5am until 9pm. Rh.VEGF-A165a  was administered at 1nM based on preliminary 
investigations that produced a VEGF-A dose response to melatonin from PT 
primary cells in culture.  
 
Total protein quantification 
Measurement of total protein was determined using the BioRad Protein Assay. 
Each sample was measured in triplicate by adding 10μl per well (from 1:10 to 
1:200 dilution, dependent on extract source) to a 96-well protein assay plate (BD 
Falcon). Serial dilutions of BSA (1000, 500, 250, 125, 62.5, 31.25, 15.125 and 0 
ng/ml) were used to generate a standard curve. BioRad Protein Assay Dye 
Reagent (BioRad, Hemel Hemstead, UK) was diluted 1:5 in PBS, and 200μl per 
well added to samples. Finally, the concentration of total protein was measured 
using the Opsys MR plate reader (Dynex, USA) at a wavelength of 595nm and 
490nm. 
Protein extraction and VEGF-A/hormone assays  
Protein extraction from cell cultures was carried out using RIPA buffer (50 mM 
Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulphate; Sigma) with an 
additional cocktail of proteinase inhibitors and stabilizers (1:50 protease inhibitor 
cocktail (Sigma).  For both protein extracted from tissue and protein extracted 
from media, total VEGF-A and VEGF-A xxxb concentrations were determined by 
VEGF-A xxxb (DY3045, R&D Systems) and human VEGF-A (DY293B, R&D 
Systems) ELISAs. Protein was extracted from the media following the 
Trichloroacetic acid (TCA) precipitation procedure. Protein was extracted from 
tissue by homogenizing the tissue and adding a protease inhibitor cocktail, and 
RIPA buffer.  
Both ELISA methods have been previously described [63-65]. A rh.VEGF-A xxxb 
positive control was included in triplicate for the human VEGF ELISA, allowing 
calculation of VEGF-A total concentration to compensate for reduced VEGF-A xxxb 
affinity, approximately 42%, as previously published [66]. The concentration of 
endogenous prolactin in culture wells following the application PD treatments was 
measured by RIA using purified ovine prolactin for standards and iodination 
provided by A. F. Parlow (University of California, Los Angeles, USA) and the 
NIDDK National Hormone and Peptide Program (USA), and an anti-ovine PRL 
antibody (ASMcN R 50) provided by A. S. McNeilly (Medical Research Council 
Human Reproductive Sciences Unit, Edinburgh, UK), as previously described 
[61]. A linear relationship was detected when the measured hormone 
concentration (ng ⁄ ml) was plotted against the concentration of diluted serum 
samples.  





Supplementary Figure 1. Relates to figure 1. A. cDNA amplified from the pituitary pars distalis 
(PD) and pars tuberalis (PT) from ewes by primers that detect both exon 8a and exon 8b 
containing isoforms. Both bands were purified and sequenced. B Chromatogram of sequence of 
PCR products. Upper band (left) shows splicing from exon 7 to exon 8a. Lower band shows 
splicing from exon7 to exon 8b. C. MT1 receptor was co-localized with VEGF-Axxxb staining, but 
not glial cells or endothelium (Scale bar = 20 m). 




Supplementary Figure 2. Relates to figure 2. A. Pars tuberalis (PT) cells were isolated from 
sheep in the breeding season (BS) and stained for the melatonin receptor, VEGF-A and Hoescht. 
B. VEGF levels from cells cultured in the absence of melatonin.  There were no significant 
differences between VEGF-A levels from PT cells taken from the winter (blue, breeding season - 
BS), or summer (red, non-breeding season – NBS) ewes. C. VEGF levels did not alter over 6 
days in primary culture (Scale bar = 20m).  
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Supplementary Figure 3 Relates to figure 4. A. Pars distalis cells from the non-breeding 
season (NBS) treated with rhVEGF-A165a in a breeding season (BS) regimen (red) do not 
produce prolactin. In contrast, cells from the BS treated with rhVEGF-A165a in a NBS manner 
(blue) did produce prolactin. B. Conditioned media from pars tuberalis (PT) cells treated with a 
NBS melatonin regimen had no effect on FSH production in PD cells, irrespective of which 
season the cells were from. C. BS cells treated with BS, but not with NBS, PT conditioned media 
produced FSH mRNA. D. NBS cells treated with CM from PT cells exposed to a BS regimen of 
melatonin produced FSH. This was blocked by incubation with an antibody to VEGF-Axxxb 
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Supplementary Table 1. Primary antibodies 
Peptide 
Target  

















VEGF=Axxxb Against human anti-
angiogenic isoforms 







Pan VEGF-A Against all isoforms 

























Abcam; ab868 Concentration 
undetermined 
by manufacturer 





Goat polyclonal  Santa Cruz; sc-
13186 
200ug/ml diluted 
1:100 to 2ug/ml 
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Goat Mouse Green (488) Life 
technologies 
A-10680 
Donkey Rabbit Red (555) Life 
technologies 
A-31572 
Streptavidin NA Green (488) Life 
technologies 
S11223 




Supplementary Table 3. Primers  
Name Sequence 
VEGF-A FWD 1 CAAATGTGAATGCAGACCAAAG 
VEGF-A REV 1 TGTGTCAGTCTTTCCTGGTGA 
VEGF-A FWD 2 CTCACCAAAGCCAGCACATAG 
VEGF-A REV 2 GACACAGAACTACCCATAGCCG 
VEGF-A FWD 3 CTCACCAAAGCCAGCACATAG 
VEGF-A REV 3 ACACAGAACTACCCATAGCCG 






VEGF-A exon 7 
FWD 
ATAAAGCAAGGCAAGAAATCCCTG 
VEGF-A exon 7 
FWD2 
GAAATCCCTGTGGGCCTTGCTAGA 
 
